This is a non-core endpoint: only basic statistics are computed.
See these related core endpoints for full statistics:
Use of glatiramer acetate
MSMED_GLATIRAMERACETATE
No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
1 out of 7 registries used, show all original rules. |
684 |
4. Check minimum number of events
Min. number of events
3
|
684 |
5. Include endpointsNone |
684 |
6. Filter based on genotype QC (FinnGen only) |
626 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- First used in FinnGen datafreeze
- DF2
Similar endpoints
↥List of similar endpoints to
Use of glatiramer acetate
based on the number of shared cases.
Similar with more cases:
- MS-disease / Multiple Sclerosis
- Demyelinating diseases of the central nervous system
- Other degenerative diseases of the nervous system
- Autoimmune diseases related-to ILD
- Autoimmune diseases
Similar with less cases:
None
Case counts by codes
↥Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 626 | 520 | 106 |
| Unadjusted period prevalence (%) | 0.16 | 0.18 | 0.05 |
| Median age at first event (years) | 38.48 | 37.96 | 41.03 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 652
- Matched controls
- 6520
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
H46
ICD-10 Finland
Optic neuritis
95.7
307.7
222
35
L03AB07
ATC
interferon beta-1a; parenteral
329.0
307.7
328
20
G37.9
ICD-10 Finland
Demyelinating disease of central nervous system, unspecified
102.7
307.7
190
26
L04AX07
ATC
dimethyl fumarate; oral
146.9
307.7
165
15
303
Kela drug reimbursment
Dimethyl fumarate, interferon beta, glatiramer acetate and teriflunomid (Multiple sclerosis)
6500.3
307.7
631
30
109
Kela drug reimbursment
Multiple sclerosis
6343.9
307.7
634
36
164
Kela drug reimbursment
Fingolimod
279.8
307.7
196
10
N86
ICPC
Multiple sclerosis
282.3
307.7
286
18
L03AX13
ATC
glatiramer acetate; parenteral
+∞
307.7
652
5
N04BB01
ATC
amantadine; oral
98.2
307.7
189
27
157
Kela drug reimbursment
Dimethyl fumarate, glatiramer acetate, interferon beta and teriflunomid (Multiple sclerosis)
1634.4
307.7
582
33
G35
ICD-10 Finland
Multiple sclerosis
+∞
307.7
652
54
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
31.4
307.7
416
347
M03BX01
ATC
baclofen; systemic
36.9
242.8
158
56
L03AB08
ATC
interferon beta-1b; parenteral
584.8
183.9
174
*
TAB00
NOMESCO Finland
Lumbar puncture
14.3
180.1
188
180
353
Kela drug reimbursment
Cladribine and fingolimod
284.3
172.5
169
8
XCK00
NOMESCO Finland
Perimetry
17.1
165.0
149
111
L04AA27
ATC
[U] fingolimod
302.0
163.5
160
7
XKD06
NOMESCO Finland
Physiologic investigation of micturition
29.2
162.0
112
46
AA1CM
NOMESCO Finland
Extensive MRI examination of brain with 3 Tesla magnet
25.5
161.5
118
56
G04BD09
ATC
trospium; oral
37.6
160.9
102
32
N06BA07
ATC
modafinil; oral
81.3
158.8
85
12
NA7CG
NOMESCO Finland
Spine and spinal cord extensive MRI examination with high intensity magnet
35.4
158.0
102
34
XA800
NOMESCO Finland
Neuropsychological investigation
12.9
152.5
167
170
XKD00
NOMESCO Finland
Uroflowmetry
12.7
147.7
162
165
L04AA31
ATC
[U] teriflunomide
232.4
145.4
145
8
ZX120
NOMESCO Finland
Intravenous
9.7
138.4
194
274
G04BD12
ATC
mirabegron; oral
9.9
130.9
176
235
Z01.0
ICD-10 Finland
Examination of eyes and vision
6.5
118.6
275
655
N07XX09
ATC
[U] dimethyl fumarate
163.0
116.6
120
9
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
7.3
109.8
199
369
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
13.4
107.1
108
95
KC1EE
NOMESCO Finland
Ultrasound measurement of residual urine
10.2
105.3
132
159
TKC22
NOMESCO Finland
Catheterisation instruction
32.7
99.3
65
22
NA1CG
NOMESCO Finland
Cervical spine extensive MRI examination with high intensity magnet
16.6
93.7
82
56
N31.9
ICD-10 Finland
Neuromuscular dysfunction of bladder, unspecified
49.0
92.1
54
12
XKC03
NOMESCO Finland
Water cystometry
15.2
91.2
84
63
G04BD07
ATC
tolterodine; oral
13.2
88.7
89
77
N03AE01
ATC
clonazepam; systemic
8.9
88.2
121
162
H02AB04
ATC
methylprednisolone; systemic
5.6
87.9
220
545
G04BD04
ATC
oxybutynin; oral, transdermal
11.2
87.0
98
101
R1250
NOMESCO Finland
Evaluation of functional capability
13.8
86.4
84
69
G04BD08
ATC
solifenacin; oral
9.7
79.2
100
120
UKC02
NOMESCO Finland
Cystoscopy
6.3
79.1
156
308
2AB04, ,
NOMESCO Finland
135.6
79.0
83
7
SPAT1229
SPAT
Assessment of need for aid
9.5
71.1
90
108
KCV12
NOMESCO Finland
Urinary bladder endoscopic botulin therapy
38.3
69.0
43
12
R20.2
ICD-10 Finland
Paraesthesia of skin
5.5
64.5
145
320
G04BD11
ATC
fesoterodine; oral
21.1
63.9
49
25
NA2CG
NOMESCO Finland
Thoracal spine extensive MRI examination with high intensity magnet
24.1
62.1
45
20
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
5.5
61.0
137
301
G97.0
ICD-10 Finland
Cerebrospinal fluid leak from spinal puncture
12.4
60.4
62
55
F02.89*G35
ICD-10 Finland
Dementia in multiple sclerosis
325.7
59.3
59
*
L04AE01
ATC
fingolimod; oral
621.1
58.6
57
*
H53.2
ICD-10 Finland
Diplopia
10.0
56.1
67
74
NA1BG
NOMESCO Finland
Cervical spine MRI examination with high intensity magnet
6.0
55.5
109
211
N03AX12
ATC
[U] gabapentin; oral
4.1
55.4
197
621
R33
ICD-10 Finland
Retention of urine
9.0
53.1
69
85
L04AG12
ATC
ofatumumab; parenteral
288.3
53.0
53
*
XCW99
NOMESCO Finland
Other investigative procedure of eye
5.4
52.9
117
252
KH1AE
NOMESCO Finland
Urinary tract ultrasound examination
7.8
52.8
78
112
O99.3
ICD-10 Finland
Mental disorders and diseases of the nervous system complicating pregnancy, childbirth and the puerperium
8.2
52.8
74
100
G36.9
ICD-10 Finland
Acute disseminated demyelination, unspecified
146.9
51.7
54
*
Z2445
NOMESCO Finland
Psychologist
6.2
47.6
88
160
TAB22
NOMESCO Finland
Stoppin epidural fluid escape with coagulated blood
11.2
47.0
51
49
N28
ICPC
Limited function/disability (N)
20.0
46.0
36
19
4AA23, ,
NOMESCO Finland
129.3
45.4
48
*
Z3226
NOMESCO Finland
Physiotherapist
3.6
42.9
183
641
NA7DG
NOMESCO Finland
Spine and spinal cord very extensive MRI examination with high intensity magnet
14.1
42.9
40
30
A28
ICPC
Limited function/disability NOS
4.7
42.4
112
278
A06AD11
ATC
lactulose; oral
4.6
39.8
105
260
XKD03
NOMESCO Finland
Urethral pressure profilometry
11.4
38.6
41
38
TKC20
NOMESCO Finland
Catheterisation of bladder
6.5
38.4
66
111
R35
ICD-10 Finland
Polyuria
5.5
37.9
79
160
N31.8
ICD-10 Finland
Other neuromuscular dysfunction of bladder
55.9
35.8
42
8
R2130
NOMESCO Finland
Counselling and guidance which enhance independent living
4.5
35.1
95
239
3400A
ICD-9 Finland
Multiple sclerosis[SCLEROSIS MULTIPLEX (DISSEMINATA)]
190.2
35.1
36
*
N05CF01
ATC
zopiclone; oral
2.8
34.6
264
1272
R5110, ,
SPAT
4.7
33.4
84
199
C10AC01
ATC
colestyramine; oral
6.9
33.3
53
82
L28
ICPC
Limited function/disability (L)
3.5
33.1
138
470
NA2BG
NOMESCO Finland
Thoracal spine MRI examination with high intensity magnet
7.3
33.1
50
73
L04AK02
ATC
teriflunomide; oral
95.2
33.1
36
*
L03AB13
ATC
peginterferon beta-1a; parenteral
123.1
33.0
35
*
N03AX16
ATC
[U] pregabalin
2.9
32.5
209
915
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
4.6
32.1
83
201
J01EA01
ATC
trimethoprim; systemic
2.7
32.0
250
1210
H48.1*G35
ICD-10 Finland
Retrobulbar neuritis in multiple sclerosis
168.0
31.0
32
*
SPAT1230
SPAT
Aid fitting and borrowing and monitoring of use
3.4
30.7
129
440
Z03.3
ICD-10 Finland
Observation for suspected nervous system disorder
4.9
30.7
72
161
Z3231
NOMESCO Finland
Registered nurse
2.7
30.7
229
1079
R4150
NOMESCO Finland
Neuropsychological rehabilitation
11.2
30.7
33
31
XCD10
NOMESCO Finland
Electrophysiological examination of eye
8.4
29.3
39
49
R4120
NOMESCO Finland
Occupational therapy
4.2
28.7
83
219
L04AX01
ATC
azathioprine; systemic
5.1
28.7
64
137
N39.0
ICD-10 Finland
Urinary tract infection, site not specified
3.1
28.4
145
554
L04AA52
ATC
[U] ofatumumab; parenteral
+∞
28.3
27
*
N02BF01
ATC
gabapentin; oral
3.3
27.9
120
414
Z46.8
ICD-10 Finland
Fitting and adjustment of other specified devices
8.3
27.5
37
47
G95.8
ICD-10 Finland
Other specified diseases of spinal cord
55.9
27.4
32
6
SPAT1223
SPAT
Implementation of physical therapy rehabilitation plan
2.6
26.8
202
946
L04AA40
ATC
cladribine; oral
146.0
26.8
28
*
G04CA02
ATC
tamsulosin; oral
3.9
25.7
81
227
SPAT1215
SPAT
Assessment of need for medical rehabilitation
5.0
23.8
53
113
N29
ICPC
Neurological sympt/complt other
7.7
23.1
33
45
N32.83
ICD-10 Finland
Nozzle synergy in the bladder neck
124.4
22.7
24
*
R4110
NOMESCO Finland
Physiotherapy
2.4
22.6
209
1066
N39.4
ICD-10 Finland
Other specified urinary incontinence
3.6
22.4
80
244
N03AF01
ATC
carbamazepine; oral, rectal
4.3
22.1
59
146
CK2X4
NOMESCO Finland
Optical coherence tomography (OCT) of ocular fundus
3.7
21.8
74
218
N31.1
ICD-10 Finland
Reflex neuropathic bladder, not elsewhere classified
29.2
21.1
28
10
U13
ICPC
Bladder symptom/complaint other
6.1
20.3
36
62
N06AX16
ATC
venlafaxine; oral
2.5
20.1
165
792
G04CA01
ATC
alfuzosin; oral
4.3
19.6
53
132
G36.0
ICD-10 Finland
Neuromyelitis optica [Devic]
72.1
18.8
21
*
H02AB07
ATC
prednisone; oral
2.7
18.4
109
445
U07
ICPC
Urine symptom/complaint other
3.3
18.4
74
243
H49.2
ICD-10 Finland
Sixth [abducent] nerve palsy
22.5
18.3
26
12
N30.0
ICD-10 Finland
Acute cystitis
2.4
18.3
161
794
N30.9
ICD-10 Finland
Cystitis, unspecified
3.4
18.2
68
213
U04
ICPC
Incontinence urine
4.5
18.1
45
105
L04AX09
ATC
diroximel fumarate; oral
+∞
17.8
17
*
A02BC02
ATC
pantoprazole; systemic
2.2
17.7
465
3479
RF120, ,
NOMESCO Finland
16.2
17.6
28
18
Z50.9
ICD-10 Finland
Care involving use of rehabilitation procedure, unspecified
4.0
17.6
51
134
WD325
NOMESCO Finland
Demanding therapy of methastized malignancy with biomodifiers
15.3
17.3
28
19
Z50.1
ICD-10 Finland
Other physical therapy
4.3
17.1
46
114
TPH04
NOMESCO Finland
Cathetrisation of vein
2.3
16.9
154
769
N06AX21
ATC
duloxetine; oral
2.5
16.8
127
583
KA1AE
NOMESCO Finland
Kidney ultrasound examination
6.7
16.8
27
42
H51.2
ICD-10 Finland
Internuclear ophthalmoplegia
+∞
16.7
16
*
N31.2
ICD-10 Finland
Flaccid neuropathic bladder, not elsewhere classified
16.9
16.7
26
16
SPAT1231
SPAT
Assessment of adjustments needed in living environment
16.9
16.7
26
16
H53.1
ICD-10 Finland
Subjective visual disturbances
3.0
15.7
74
266
N04BC05
ATC
pramipexole; oral
3.4
15.6
60
191
G50.0
ICD-10 Finland
Trigeminal neuralgia
5.2
15.4
32
64
N06AB04
ATC
citalopram; systemic
2.1
15.2
171
926
SPAT1216
SPAT
Assessment of functional ability
2.8
14.9
82
321
J01CA08
ATC
pivmecillinam; oral
1.9
14.5
355
2511
R39.1
ICD-10 Finland
Other difficulties with micturition
5.5
14.3
28
53
U05
ICPC
Urination problems other
4.2
14.2
38
94
SPAT1220
SPAT
Assessment of need for rehabilitation and/or rehabilitation plan
3.9
14.2
42
112
U08
ICPC
Urinary retention
14.9
14.1
23
16
K59.00
ICD-10 Finland
Constipation caused by slow bowel passage (SCT)
6.9
14.1
22
33
RS221, ,
NOMESCO Finland
6.4
13.8
23
37
CS444
NOMESCO Finland
Visual field testing with Octopus automated perimetry
4.6
13.7
33
75
SPAT1262
SPAT
Handing over of treatment supplies
2.4
13.6
100
451
R5110
NOMESCO Finland
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
2.5
13.6
97
432
N10
ICD-10 Finland
Acute tubulo-interstitial nephritis
2.7
13.5
81
331
NA3BG
NOMESCO Finland
Lumbar spine MRI examination with high intensity magnet
2.5
13.4
92
402
OAB50, ,
SPAT
3.0
13.0
60
213
Z2446
NOMESCO Finland
Social worker
2.9
12.9
62
225
NA7BG
NOMESCO Finland
Spine and spinal cord MRI examination with high intensity magnet
14.4
12.8
21
15
N06AA09
ATC
amitriptyline; systemic
2.7
12.7
71
280
N32.82
ICD-10 Finland
Instability of the detrusor vesicae muscle
12.6
12.7
22
18
34099
ICD-8 Finland
Multiple sclerosis
+∞
12.5
12
*
N31.0
ICD-10 Finland
Uninhibited neuropathic bladder, not elsewhere classified
24.9
12.5
17
7
G04BD10
ATC
darifenacin; oral
38.3
12.2
15
*
H47.2
ICD-10 Finland
Optic atrophy
38.3
12.2
15
*
R42
ICD-10 Finland
Dizziness and giddiness
2.1
12.2
139
749
N02BF02
ATC
pregabalin; oral
2.8
12.0
65
252
N99
ICPC
Neurological disease other
10.8
11.8
22
21
RF420, ,
NOMESCO Finland
8.9
11.6
24
28
CK2S4
NOMESCO Finland
Plain photography of ocular fundus
3.4
11.6
42
129
G37.3
ICD-10 Finland
Acute transverse myelitis in demyelinating disease of central nervous system
+∞
11.5
11
*
4AA36, ,
NOMESCO Finland
122.1
11.5
12
*
R15
ICD-10 Finland
Faecal incontinence
5.3
11.3
23
45
ZXE15
NOMESCO Finland
Procedure duration 120 to 149 minutes
4.5
11.3
28
65
M03BX02
ATC
tizanidine; oral
1.9
11.3
473
3819
N03AF02
ATC
oxcarbazepine; oral
3.5
11.3
39
116
SPAT1137
SPAT
Taking care of patient’s/customer’s hygiene
5.5
10.9
21
39
R32
ICD-10 Finland
Unspecified urinary incontinence
4.8
10.8
24
51
359
Kela drug reimbursment
Mirabegroni
28.6
10.8
14
5
N04BD01
ATC
selegiline; oral
13.2
10.7
18
14
Z43.5
ICD-10 Finland
Attention to cystostomy
61.0
10.7
12
*
K59.09
ICD-10 Finland
Constipation, unspecified
3.1
10.6
44
147
RF410, ,
NOMESCO Finland
9.4
10.6
21
23
AA1DM
NOMESCO Finland
Very extensive MRI examination of brain with 3 Tesla magnet
10.3
10.6
20
20
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
2.6
10.5
64
263
CS494
NOMESCO Finland
Other visual field testing
5.5
10.5
20
37
H47.0
ICD-10 Finland
Disorders of optic nerve, not elsewhere classified
111.8
10.4
11
*
RS340, ,
NOMESCO Finland
+∞
10.4
10
*
3773B
ICD-9 Finland
Disorders of optic nerve and visual pathways, Optic neuritis[NEURITIS RETROBULBARIS]
+∞
10.4
10
*
308
Kela drug reimbursment
Alprostadil, sildenafil and combination product containing aviptadil and phentolamine
16.4
10.4
16
10
GD1AA
NOMESCO Finland
Thorax X-ray examination
1.7
10.4
252
1726
TKC10
NOMESCO Finland
Percutaneous puncture of bladder
19.1
10.3
15
8
R4110, ,
SPAT
2.2
10.2
90
437
OAB43, ,
SPAT
0.6
10.0
197
2831
SPAT1325
SPAT
Vaccination
1.8
9.9
172
1064
DM1QA
NOMESCO Finland
Paranasal sinuses X-ray examination in one projection
3.0
9.9
44
153
XF400
NOMESCO Finland
ECG with 12 standard connections
2.3
9.9
80
375
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
1.8
9.8
172
1066
J05AB01
ATC
aciclovir; systemic
1.8
9.8
177
1107
U02
ICPC
Urinary frequency/urgency
2.1
9.8
106
558
K59.0
ICD-10 Finland
Constipation
3.2
9.8
38
122
J01MA02
ATC
ciprofloxacin; systemic
1.7
9.7
224
1505
NA3CG
NOMESCO Finland
Lumbar spine extensive MRI examination with high intensity magnet
3.4
9.6
34
103
C03CA01
ATC
furosemide; systemic
2.2
9.6
87
428
XCK10
NOMESCO Finland
Photography of fundus of eye
2.6
9.6
55
220
R5130, ,
SPAT
101.5
9.4
10
*
R60.0
ICD-10 Finland
Localized oedema
2.3
9.4
73
336
ABD40
NOMESCO Finland
Implantation of spinal injection device
+∞
9.4
9
*
A06AC01
ATC
ispaghula (psylla seeds); oral
1.8
9.3
160
984
N18
ICPC
Paralysis/weakness
9.7
8.8
17
18
G04BE03
ATC
sildenafil; oral
14.3
8.7
14
10
SPAT1167
SPAT
Insertion of urinary catheter
8.4
8.6
18
22
A02BA02
ATC
ranitidine; systemic
2.0
8.5
104
571
RF432, ,
NOMESCO Finland
+∞
8.3
8
*
H48.1
ICD-10 Finland
Retrobulbar neuritis in diseases classified elsewhere
+∞
8.3
8
*
A04
ICPC
Weakness/tiredness general
1.9
8.3
112
635
H55
ICD-10 Finland
Nystagmus and other irregular eye movements
9.6
8.3
16
17
SPAT1217
SPAT
Assessment of need for services (elderly/care support)
4.3
8.2
21
50
SPAT1222
SPAT
Counselling/guidance promoting independent living
2.2
8.2
69
329
W01
ICD-10 Finland
Fall on same level from slipping, tripping and stumbling
1.8
8.2
159
1011
119
Kela drug reimbursment
Trigeminal neuralgia or glossofaryngeusneuralgia
17.4
8.1
12
7
CS5Z4
NOMESCO Finland
Specialised imaging for glaucoma
4.7
7.9
18
39
Z3229
NOMESCO Finland
Other healthcare associate professional
2.5
7.9
51
216
M05BX04
ATC
denosumab; parenteral
3.6
7.9
26
75
L89
ICD-10 Finland
Decubitus ulcer and pressure area
9.6
7.8
15
16
6BA02, ,
NOMESCO Finland
15.2
7.7
12
8
G04BDXX, ,
ATC
45.5
7.7
9
*
WW400
NOMESCO Finland
Plasmaferesis
45.5
7.7
9
*
N06CA01
ATC
amitriptyline and psycholeptics; systemic
2.2
7.7
68
331
U29
ICPC
Urinary symptom/complaint other
3.7
7.6
24
67
NA1DG
NOMESCO Finland
Cervical spine very extensive MRI examination with high intensity magnet
18.6
7.6
11
6
R03CA02
ATC
ephedrine; oral
25.3
7.6
10
*
SPAT1226
SPAT
Implementation of occupational therapy rehabilitation plan
6.3
7.6
19
31
Z01.2
ICD-10 Finland
Dental examination
1.6
7.6
343
2688
SPAT1256
SPAT
Intramuscular and subcutaneous injection
1.6
7.5
220
1555
L01BB04
ATC
cladribine; systemic
81.0
7.4
8
*
CA1CG
NOMESCO Finland
Eye and orbita extensive MRI examination with high intensity magnet
9.5
7.3
14
15
Z93.5
ICD-10 Finland
Cystostomy status
+∞
7.3
7
*
M05BA04
ATC
alendronic acid; oral
3.1
7.3
30
100
R51.80
ICD-10 Finland
Headache
1.7
7.2
137
862
J05AB11
ATC
valaciclovir; oral
1.8
7.2
110
650
R4120, ,
SPAT
6.7
7.1
17
26
H57.1
ICD-10 Finland
Ocular pain
2.5
7.1
43
177
G51.0
ICD-10 Finland
Bell palsy
3.7
7.1
22
61
R06AE07
ATC
cetirizine; oral
1.6
7.1
324
2533
U28
ICPC
Limited function/disability (U)
14.0
6.9
11
8
R31
ICD-10 Finland
Unspecified haematuria
2.6
6.9
39
155
F32.9
ICD-10 Finland
Depressive episode, unspecified
1.8
6.8
115
698
J01AA02
ATC
doxycycline; systemic
1.7
6.8
505
4391
AA1AD
NOMESCO Finland
CT of head and brain
1.7
6.7
132
837
H02AB06
ATC
prednisolone; systemic
1.5
6.7
294
2267
G82.2
ICD-10 Finland
Paraplegia, unspecified
22.8
6.7
9
*
H19.2*B02.3
ICD-10 Finland
Keratitis and keratoconjunctivitis (interstitial) in zoster
22.8
6.7
9
*
H53.4
ICD-10 Finland
Visual field defects
4.1
6.7
18
45
M81.9
ICD-10 Finland
Osteoporosis, unspecified
3.6
6.6
21
59
H52.1
ICD-10 Finland
Myopia
2.4
6.6
43
183
RS230, ,
NOMESCO Finland
10.2
6.6
12
12
SPAT1263
SPAT
Sampling
1.5
6.5
251
1879
1DB07, ,
NOMESCO Finland
70.5
6.4
7
*
RF310, ,
NOMESCO Finland
70.5
6.4
7
*
Z01.8
ICD-10 Finland
Other specified special examinations
1.7
6.4
145
954
R1230
NOMESCO Finland
Neuropsychological evaluation of need and possibilities to rehabilitation
8.3
6.4
13
16
J01MA06
ATC
norfloxacin; oral
1.9
6.3
86
489
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
2.2
6.3
56
273
N07AA03
ATC
distigmine; systemic
26.9
6.2
8
*
Y57
ICD-10 Finland
Adverse effects in the therapeutic use of other and unspecified drugs and medicaments
3.5
6.2
21
62
N06AX12
ATC
bupropion; oral
1.9
6.1
77
426
R13
ICD-10 Finland
Dysphagia
2.4
6.1
43
190
J01XX05
ATC
methenamine; oral
8.7
6.1
12
14
L95
ICPC
Osteoporosis
3.9
6.0
17
44
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
198
115
24.29
252.46
1.2
1.1
—
—
—
0
0
127
14
112.42
247.28
3.3
3.4
—
—
—
0
0
193
218
12.16
164.75
1.8
1.6
0.01
0.01
iu/ml
—
8
23
113
50
27.13
158.91
4.1
2.6
1296.87
1268.07
e6/l
0.10
100
45
268
479
8.80
157.94
4.3
2.6
9.47
10.37
g/l
4.88
251
449
92
36
29.59
134.80
4.3
2.6
469.07
457.93
e6/l
0.08
76
29
206
373
7.61
116.81
4.0
1.7
0.96
1.23
g/l
5.39
200
354
73
38
21.51
95.06
2.9
2.3
—
—
—
0
0
574
3099
8.12
85.56
18.0
6.2
1.58
1.96
e9/l
13.16
551
2814
66
36
20.29
84.00
1.2
1.1
1815.70
1667.08
miu/ml
0.29
66
36
569
3356
6.46
67.60
17.9
9.1
3.59
3.95
e9/l
5.96
546
2975
283
1044
4.02
64.99
4.8
2.4
4.38
8.19
e6/l
3.92
262
948
73
79
10.28
62.14
1.2
1.1
—
—
—
0
0
59
49
13.14
59.85
1.0
1.1
—
—
—
0
0
346
1564
3.58
56.68
6.8
2.7
16.66
49.50
e6/l
2.18
301
1154
568
3615
5.43
54.13
11.1
3.8
72.64
432.26
e6/l
0.51
11
38
60
61
10.73
53.24
1.1
1.1
49.47
31.45
mg/l
2.57
42
47
310
1359
3.44
52.36
6.2
2.6
0.15
0.34
e6/l
2.14
262
952
58
58
10.88
52.04
1.1
1.1
206.99
223.37
mg/l
0.35
42
49
54
50
11.68
51.01
1.3
1.2
0.89
0.52
ratio
3.13
18
25
460
2675
3.44
46.60
3.1
2.5
96.91
74.64
nmol/l
32.02
439
2539
499
3112
3.57
43.71
7.0
3.3
0.00
0.01
estimate
1.08
121
602
493
3057
3.51
43.49
7.1
3.3
0.00
0.00
estimate
0.50
121
632
494
3094
3.46
42.26
7.1
3.3
0.00
4.61
estimate
0.80
123
633
203
803
3.22
38.68
5.4
2.3
0.90
0.96
e6/l
0.12
123
381
77
160
5.32
35.83
1.1
1.4
412.35
445.05
mg/l
0.48
71
151
182
725
3.10
33.72
5.7
2.4
5.67
3.86
e6/l
0.65
103
306
49
69
7.60
33.49
1.1
1.1
—
—
—
0
0
69
142
5.32
32.39
1.2
1.6
8.08
9.60
e6/l
0.12
52
105
48
69
7.43
32.20
1.0
1.1
—
—
—
0
0
38
9
44.66
31.22
1.2
1.0
—
—
—
0
0
68
144
5.16
30.87
1.3
1.7
542.67
150.99
e6/l
0.49
52
112
48
74
6.92
30.21
1.1
1.1
—
—
—
0
0
90
251
4.00
28.84
1.6
1.4
—
—
—
0
0
37
50
7.79
26.12
1.0
1.1
0.94
1.11
u/l
1.11
12
24
413
2771
2.34
23.58
6.4
5.8
9.30
9.94
umol/l
1.42
398
2644
276
1594
2.27
22.25
7.9
3.4
0.00
0.00
estimate
1.08
119
611
124
501
2.82
21.57
2.7
2.1
5288.88
5795.03
u/l
0.05
38
212
57
149
4.10
19.81
1.1
1.3
3.58
3.59
mmol/l
0.04
51
142
142
640
2.56
19.77
2.3
2.0
29.32
29.34
s
0.02
135
624
351
2402
2.00
16.59
7.5
3.0
0.00
0.04
estimate
2.58
107
540
20
5
41.23
16.41
1.1
1.2
—
—
—
0
0
283
1869
1.91
14.16
6.2
2.7
0.01
0.02
estimate
0.42
109
530
233
1466
1.92
13.33
2.8
1.4
1.90
2.20
g/l
3.62
182
991
311
2152
1.85
13.16
4.7
4.7
37.26
37.29
g/l
0.04
295
2052
512
4202
2.02
12.15
7.8
7.4
74.35
74.73
u/l
0.08
490
4031
480
5509
0.51
11.84
3.3
3.7
1.31
1.25
mmol/l
0.84
453
5276
41
127
3.38
11.13
1.9
2.8
2.31
1.85
index
0.18
16
59
523
5819
0.49
11.01
3.9
4.3
1.50
1.50
mmol/l
0.17
486
5602
51
188
2.86
10.34
1.6
1.6
—
—
—
0
0
204
1317
1.80
10.25
7.6
3.2
1.02
2.18
kg/l
0.50
160
866
529
5835
0.50
9.73
4.0
4.4
4.92
4.85
mmol/l
1.05
497
5646
533
5864
0.50
9.69
4.3
4.7
2.96
2.90
mmol/l
0.82
497
5650
24
57
4.33
9.45
1.2
1.5
—
—
—
0
0
379
3009
1.62
8.18
4.8
4.4
6.04
6.36
mmol/l
3.45
363
2789
115
687
1.82
7.23
1.9
1.8
—
—
—
0
0
88
485
1.94
7.09
1.8
1.7
—
—
—
0
0
283
2174
1.53
6.51
5.5
3.2
28.32
29.27
u/l
0.25
272
2078
104
625
1.79
6.38
2.6
2.6
6.55
5.35
umol/l
0.56
96
536
300
2346
1.52
6.28
7.1
6.3
1.22
1.22
mmol/l
0.26
256
2050
620
5792
2.44
5.98
17.1
11.7
19.57
19.32
mg/l
0.07
517
4627
58
1044
0.51
5.69
1.7
1.9
3.03
3.36
ratio
1.33
39
789
609
5666
2.13
5.64
15.9
11.8
139.84
139.67
mmol/l
1.29
603
5576
610
5679
2.15
5.63
16.0
11.9
3.90
3.91
mmol/l
0.88
602
5572
81
478
1.79
5.27
1.9
1.7
—
—
—
0
0
41
806
0.48
5.21
1.4
1.7
3.08
3.44
mmol/l
1.19
25
554
640
6120
3.49
4.98
21.3
10.2
27.27
26.13
u/l
1.12
632
6026
259
2052
1.43
4.68
6.9
5.7
1.22
1.22
mmol/l
0.32
241
1925
486
5312
0.67
4.64
4.4
4.8
36.25
37.62
mmol/mol
3.71
457
5128
594
5535
1.82
4.63
15.4
10.2
95.94
91.52
ml/min/173m2
8.35
556
5050
502
4523
1.48
4.21
5.5
3.2
49.27
38.83
u/l
1.58
481
4393
262
2123
1.39
4.01
2.0
1.9
101.01
97.98
pmol/l
0.44
138
1190
169
1269
1.45
3.97
1.7
1.6
20.64
20.70
nmol/l
0.02
148
1143
191
1467
1.43
3.97
2.2
2.0
183.43
195.43
u/l
0.07
186
1406
100
1427
0.65
3.92
1.3
1.4
9.45
23.38
iu/ml
7.03
21
441
90
1307
0.64
3.81
1.3
1.3
1.59
11.15
u/ml
5.37
33
569
118
840
1.49
3.62
2.7
2.9
279.69
356.26
ng/l
0.17
54
454
634
6108
2.38
3.43
21.3
13.6
66.54
68.76
umol/l
1.01
634
6065
13
44
2.99
3.15
1.8
1.5
48.17
17.80
mg/l
—
6
24
39
220
1.82
3.00
2.9
2.2
10.94
4.66
iu/l
1.24
18
94
8
17
4.75
2.92
2.4
1.9
41.07
54.31
ug/l
—
8
17
11
33
3.37
2.82
2.2
3.1
14.00
15.65
index
—
6
17
7
15
4.70
2.60
1.1
1.1
82.43
98.87
%
—
7
15
35
206
1.74
2.39
5.9
2.3
1.02
1.02
ratio
0.97
27
191
76
540
1.46
2.37
7.9
6.9
104.45
104.69
mmol/l
0.19
76
540
18
348
0.50
2.23
1.4
1.7
2.29
3.05
mg/l
—
9
245
22
114
1.96
2.23
1.1
1.9
0.00
0.00
g/l
-0.00
22
108
22
396
0.54
2.18
1.1
1.1
0.94
0.89
g/l
0.59
22
396
20
101
2.01
2.17
1.2
1.2
—
—
—
0
0
497
5262
0.77
2.15
30.5
14.7
332.59
332.65
g/l
0.06
497
5234
22
392
0.55
2.11
1.1
1.1
1.57
1.57
g/l
0.02
22
392
23
126
1.86
2.00
1.5
1.9
0.53
0.45
g/l
0.05
23
119
22
385
0.56
2.00
1.3
1.5
—
—
—
0
0
28
165
1.73
1.94
2.0
3.7
25.93
25.10
mmol/l
0.53
28
159
6
16
3.77
1.94
1.2
1.3
658.65
975.69
u/l
—
6
16
11
45
2.47
1.94
1.0
1.1
132.18
122.49
pmol/l
0.13
11
45
16
78
2.08
1.92
2.1
3.9
1.74
1.68
ratio
—
10
41
51
350
1.50
1.92
1.1
1.3
257.78
236.29
miu/ml
0.12
18
183
0
51
0.00
1.89
0.0
1.1
—
7.59
—
0
51
21
114
1.87
1.89
1.6
2.1
316.14
252.14
ug/l
0.19
21
102
105
823
1.33
1.86
2.6
2.3
15.76
14.87
umol/l
0.46
99
771
13
59
2.23
1.85
1.5
1.2
—
—
—
0
0
6
17
3.55
1.84
1.0
4.1
1.17
0.71
index
—
6
17
198
1690
1.25
1.80
2.5
2.6
50.69
59.38
u/l
1.96
185
1602
8
30
2.69
1.73
1.1
1.1
—
—
—
0
0
69
513
1.39
1.72
2.4
2.3
24.49
35.66
u/l
2.45
49
432
27
164
1.67
1.70
1.8
1.9
—
—
—
0
0
519
5425
0.79
1.64
3.8
4.1
5.59
5.69
mmol/l
1.44
478
5182
25
151
1.68
1.62
2.6
2.1
1.49
1.39
g/l
0.26
20
133
25
151
1.68
1.62
1.8
1.8
—
—
—
0
0
52
372
1.43
1.62
8.1
3.4
5.86
5.78
kpa
0.28
52
362
191
1646
1.23
1.57
1.6
1.6
—
—
—
0
0
6
21
2.87
1.51
1.2
1.9
60.83
109.41
ng/l
—
6
21
113
924
1.27
1.48
2.3
2.8
598.13
527.69
ng/l
0.13
94
753
577
5565
1.32
1.47
7.0
5.6
1.60
1.73
mu/l
2.41
556
5372
455
4806
0.82
1.46
3.7
3.8
—
—
—
0
0
18
103
1.77
1.42
2.0
3.7
27.50
33.62
umol/l
1.16
18
95
78
614
1.31
1.37
1.6
1.6
1096.92
1172.19
nmol/l
0.35
62
498
5
17
2.96
1.36
1.2
1.1
78.80
78.35
ug/l
—
5
17
0
38
0.00
1.34
0.0
1.1
—
46.31
—
0
38
15
83
1.83
1.32
1.1
1.2
—
—
—
0
0
15
83
1.83
1.32
1.1
1.2
—
—
—
0
0
12
219
0.54
1.32
1.3
1.4
82.32
128.57
pmol/l
0.38
12
212
455
4296
1.20
1.30
3.3
4.0
10.19
9.11
mm/h
1.06
428
4106
31
210
1.50
1.30
2.1
2.6
155.63
73.11
ng/l
0.38
24
188
112
1335
0.81
1.29
1.8
2.3
295.54
310.34
umol/l
0.94
104
1237
12
62
1.95
1.28
1.2
1.1
260.75
288.49
mg/l
0.77
12
57
9
44
2.06
1.27
1.0
1.2
—
—
—
0
0
19
115
1.67
1.26
1.1
1.9
0.00
0.00
g/l
-0.00
19
103
43
315
1.39
1.22
2.0
1.7
—
—
—
0
0
20
124
1.63
1.22
1.0
1.3
1.25
3.68
u/ml
—
8
44
5
19
2.64
1.22
1.0
3.5
—
—
—
0
0
13
72
1.82
1.15
1.9
1.8
—
—
—
0
0
20
126
1.61
1.15
1.0
1.3
2.83
5.60
u/ml
—
6
50
75
923
0.79
1.15
2.0
1.8
1.54
1.35
%
1.92
65
841
0
36
0.00
1.14
0.0
10.7
—
45.57
—
0
14
29
200
1.47
1.14
11.4
2.5
0.62
0.64
%
0.13
29
200
53
409
1.32
1.10
6.6
9.9
0.80
0.88
mmol/l
0.05
38
332
106
892
1.22
1.10
1.9
2.2
2.44
2.41
mmol/l
1.70
88
802
5
21
2.39
1.09
1.4
1.3
—
—
—
0
0
5
21
2.39
1.09
1.4
1.3
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
7
33
2.13
1.06
1.0
1.2
—
—
—
0
0
26
368
0.69
1.03
1.3
1.5
1.19
1.19
ratio
0.00
14
227
26
368
0.69
1.03
1.3
1.5
0.95
0.95
ratio
0.02
14
227
26
368
0.69
1.03
1.3
1.5
1.19
1.13
ratio
0.09
14
227
156
1371
1.18
1.03
2.2
2.1
2.68
2.60
mg/l
0.17
132
1213
15
91
1.66
1.01
1.5
2.9
—
1034.67
—
0
6
118
1365
0.83
1.01
5.1
4.0
3.82
9.86
mg/mmol
2.03
76
848
26
366
0.70
1.01
1.3
1.5
—
—
—
0
0
19
123
1.56
1.00
1.3
1.4
164.00
164.82
au/ml
—
5
31
18
116
1.57
0.97
1.8
4.2
—
330.00
—
0
10
7
36
1.95
0.97
3.3
9.6
26.30
475.43
ug/l
—
7
24
7
36
1.95
0.97
2.4
1.7
2.57
0.90
u/field
—
7
28
7
36
1.95
0.97
1.6
2.3
1.20
1.20
mmol/l
—
7
36
18
270
0.66
0.97
1.4
1.7
—
—
—
0
0
13
77
1.70
0.95
1.5
1.5
—
—
—
0
0
7
37
1.90
0.94
1.6
2.4
106.00
106.00
mmol/l
—
7
37
10
171
0.58
0.92
1.3
1.2
—
—
—
0
0
41
314
1.33
0.92
9.1
2.7
4.60
4.76
kpa
0.21
41
307
10
169
0.59
0.89
1.3
1.2
—
—
—
0
0
645
6391
1.86
0.89
33.8
18.4
4.51
4.53
e12/l
0.67
640
6310
16
103
1.57
0.88
1.5
2.0
4.60
5.22
mmol/24h
0.40
16
90
195
1768
1.15
0.86
2.1
3.1
2.34
2.35
mmol/l
0.72
174
1663
20
137
1.47
0.85
1.1
1.2
274.54
223.10
u/ml
0.31
13
85
44
346
1.29
0.84
3.0
3.7
69.18
76.93
ng/l
0.23
39
321
26
190
1.38
0.80
1.5
1.3
28.68
23.81
u/l
0.31
18
156
58
701
0.81
0.79
1.6
1.9
—
—
—
0
0
0
24
0.00
0.79
0.0
1.0
—
712.53
—
0
19
0
24
0.00
0.79
0.0
1.0
—
31.12
—
0
18
0
25
0.00
0.79
0.0
3.0
—
151.27
—
0
6
146
1305
1.15
0.78
2.2
2.0
—
—
—
0
0
0
27
0.00
0.77
0.0
1.1
—
160.46
—
0
27
53
433
1.24
0.76
2.6
2.7
—
—
—
0
0
5
24
2.09
0.74
2.4
2.7
7.90
17.33
umol/l
—
5
24
45
362
1.26
0.74
11.0
7.5
1.20
1.22
mmol/l
0.06
45
356
9
55
1.65
0.73
1.1
1.3
64.44
72.15
umol/l
—
9
55
23
310
0.73
0.73
1.5
1.8
—
—
—
0
0
11
170
0.64
0.71
1.3
1.2
—
—
—
0
0
14
205
0.68
0.71
1.1
1.1
0.37
1.47
u/ml
—
8
93
34
266
1.29
0.70
1.7
1.7
11.99
9.56
u/ml
—
8
77
112
994
1.15
0.67
1.5
1.6
479.23
35770085.30
pmol/l
1.26
101
903
13
86
1.52
0.66
3.6
2.8
1.54
1.37
mmol/l
0.43
13
81
121
1348
0.87
0.66
2.0
2.2
—
—
—
0
0
184
1694
1.12
0.63
1.4
1.3
0.87
1.91
u/ml
1.21
40
505
87
762
1.16
0.63
1.3
1.4
33.04
26.23
iu/l
0.91
75
656
11
71
1.56
0.62
1.2
1.3
—
—
—
0
0
89
784
1.16
0.60
3.1
3.1
0.82
0.82
mmol/l
0.32
84
757
56
655
0.84
0.58
1.3
1.6
1067.44
1016.73
mu/l
0.18
50
524
19
141
1.36
0.57
2.9
3.0
24.92
24.60
mmol/l
0.24
19
134
146
1591
0.89
0.56
4.5
3.2
7.81
8.05
mmol/l
0.27
123
1409
20
262
0.76
0.56
1.5
1.8
—
—
—
0
0
77
870
0.87
0.53
1.7
2.0
—
—
—
0
0
18
236
0.76
0.51
1.1
1.1
0.52
2.12
u/ml
—
9
116
57
495
1.17
0.48
5.7
5.0
—
—
—
0
0
16
120
1.34
0.46
1.8
1.6
—
—
—
0
0
8
118
0.67
0.46
1.0
1.3
—
—
—
0
0
45
385
1.18
0.46
1.4
1.6
—
—
—
0
0
185
1736
1.09
0.44
2.9
2.8
28.25
29.26
ng/l
0.04
100
859
9
130
0.69
0.43
1.4
1.5
—
—
—
0
0
5
31
1.62
0.43
1.6
3.5
862.40
1174.90
mg
—
5
31
30
249
1.21
0.42
1.2
1.2
—
—
—
0
0
8
58
1.38
0.41
1.0
1.0
—
—
—
0
0
0
15
0.00
0.41
0.0
1.9
—
—
—
0
0
0
15
0.00
0.41
0.0
1.9
—
—
—
0
0
0
15
0.00
0.41
0.0
1.9
—
—
—
0
0
0
16
0.00
0.41
0.0
1.0
—
—
—
0
0
0
16
0.00
0.41
0.0
1.3
—
—
—
0
0
16
123
1.31
0.41
1.0
1.1
—
—
—
0
0
0
17
0.00
0.40
0.0
1.1
—
—
—
0
0
37
429
0.85
0.38
1.5
1.5
—
—
—
0
0
9
68
1.33
0.37
1.3
1.3
—
—
—
0
0
8
114
0.70
0.37
1.1
1.3
—
—
—
0
0
501
4915
1.08
0.36
5.9
4.8
14.31
14.27
pmol/l
0.14
474
4702
5
77
0.65
0.36
1.2
1.6
—
—
—
0
0
6
43
1.40
0.35
1.0
1.3
—
—
—
0
0
14
178
0.78
0.34
2.4
1.6
—
—
—
0
0
36
413
0.86
0.33
1.7
2.1
87.19
77.81
ml/min/173m2
1.24
16
170
236
2460
0.94
0.33
1.8
1.9
1.46
1.39
mmol/l
0.53
197
2198
6
88
0.68
0.33
1.0
1.1
—
16.00
—
0
44
17
137
1.25
0.32
1.4
1.0
0.92
2.56
eliau/ml
—
6
73
7
52
1.35
0.31
2.0
3.6
36.43
61.10
u/ml
—
7
52
330
3397
0.94
0.31
3.3
3.2
84.92
79.60
ug/l
0.18
316
3274
148
1403
1.07
0.29
1.9
1.7
0.99
0.79
mg/l
0.41
98
1061
33
375
0.87
0.28
2.2
2.5
0.70
0.68
ug/l
0.06
19
175
61
558
1.10
0.27
3.8
3.8
30.02
31.59
%
0.76
52
429
116
1229
0.93
0.26
1.9
2.1
—
—
—
0
0
18
150
1.21
0.26
2.1
2.2
3.53
5.34
umol/l
1.34
13
113
8
67
1.20
0.26
2.5
1.8
—
—
—
0
0
11
86
1.28
0.26
1.0
1.1
—
—
—
0
0
25
216
1.16
0.26
1.1
1.3
—
2.59
—
0
22
9
73
1.24
0.25
1.4
1.2
—
—
—
0
0
46
419
1.11
0.23
1.1
1.1
—
—
—
0
0
26
228
1.15
0.23
1.4
1.5
—
—
—
0
0
5
40
1.25
0.22
1.2
1.5
7.18
6.76
u/l
—
5
35
0
11
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
0
12
0.00
0.21
0.0
1.0
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
1.4
—
—
—
0
0
0
12
0.00
0.21
0.0
1.3
—
—
—
0
0
0
12
0.00
0.21
0.0
1.3
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
0
14
0.00
0.20
0.0
5.2
—
—
—
0
0
274
2674
1.04
0.19
2.6
2.6
—
—
estimate
—
0
0
15
175
0.85
0.19
2.1
2.5
9.31
10.51
mg/l
0.29
15
166
60
561
1.08
0.18
1.2
1.3
91.59
170.94
u/ml
1.37
55
522
12
100
1.20
0.18
1.2
2.1
—
2560.00
—
0
5
8
68
1.18
0.16
1.4
1.3
—
—
—
0
0
8
69
1.16
0.16
1.4
1.3
—
—
—
0
0
8
69
1.16
0.16
1.4
1.3
—
—
—
0
0
8
72
1.11
0.16
2.5
1.9
14.14
6.55
u/ml
—
8
72
46
492
0.93
0.15
3.0
3.4
22.77
21.81
%
0.11
21
163
37
342
1.09
0.15
2.3
4.5
13.70
6.99
ug/l
0.33
25
260
36
334
1.08
0.14
1.5
1.6
0.20
0.30
mg/l
0.81
12
144
9
107
0.84
0.13
2.7
2.5
—
—
—
0
0
20
219
0.91
0.11
1.2
1.5
53.19
58.59
ug/l
0.34
20
219
10
86
1.17
0.11
1.0
1.2
—
—
—
0
0
29
270
1.08
0.10
3.1
2.8
5.25
5.11
kpa
0.45
29
262
5
44
1.14
0.10
1.2
1.2
—
—
—
0
0
18
164
1.10
0.10
1.2
1.3
—
—
—
0
0
10
87
1.15
0.09
1.3
1.4
—
—
—
0
0
16
145
1.11
0.09
1.3
1.3
—
—
—
0
0
13
116
1.12
0.09
1.8
1.8
—
—
—
0
0
12
134
0.89
0.09
1.3
1.5
—
—
—
0
0
13
117
1.11
0.08
1.3
1.4
—
—
—
0
0
7
64
1.09
0.08
1.1
1.2
—
—
—
0
0
7
65
1.08
0.08
1.4
1.3
—
—
—
0
0
7
65
1.08
0.08
1.1
1.2
—
—
—
0
0
7
66
1.06
0.08
1.4
1.3
—
—
—
0
0
7
66
1.06
0.08
1.4
1.3
—
—
—
0
0
7
67
1.05
0.08
1.1
1.2
—
—
—
0
0
7
67
1.05
0.08
1.1
1.2
—
—
—
0
0
8
75
1.07
0.07
1.5
1.5
—
—
—
0
0
7
81
0.86
0.07
1.1
1.2
—
—
—
0
0
7
80
0.87
0.07
1.3
1.3
—
—
—
0
0
18
168
1.07
0.06
1.6
1.4
284.51
321.07
ug/g
—
8
93
41
395
1.04
0.05
1.5
1.4
—
—
—
0
0
172
1698
1.02
0.05
1.6
1.7
—
—
—
0
0
32
309
1.04
0.03
1.3
1.6
—
—
—
0
0
34
349
0.97
0.02
7.0
3.2
1.24
1.23
mmol/l
0.20
27
303
37
378
0.98
0.01
1.5
1.5
—
—
—
0
0
64
634
1.01
0.00
1.3
1.3
220.70
154.45
u/ml
0.48
23
278
10
96
1.04
0.00
1.0
1.2
—
17.71
—
0
7
10
103
0.97
0.00
1.4
1.4
—
—
—
0
0
15
147
1.02
0.00
1.0
1.1
34.92
17.38
au/ml
—
5
49
6
61
0.98
0.00
2.8
1.7
0.28
1.10
promille
—
6
49
10
100
1.00
-0.00
5.3
2.1
5.41
6.90
pmol/l
—
10
100
0
6
0.00
-0.00
0.0
1.0
—
67.00
—
0
6
0
6
0.00
-0.00
0.0
1.0
—
10.38
—
0
6
0
5
0.00
-0.00
0.0
13.8
—
10.36
—
0
5
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
10.9
—
5.80
—
0
7
0
7
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
7
70
1.00
-0.00
1.1
1.2
—
—
—
0
0
5
50
1.00
-0.00
1.2
1.3
15.80
10.04
umol/l
—
5
45
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
6
67
0.89
-0.00
1.2
1.3
23.10
31.24
nmol/l
—
6
54
0
5
0.00
-0.00
0.0
4.6
—
22.80
—
0
5
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.7
—
36.03
—
0
6
0
6
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
2.39
—
0
5
0
9
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
5
0.00
-0.00
0.0
10.6
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
6.3
—
—
—
0
0
6
62
0.97
-0.00
1.0
1.1
—
60.50
—
0
6
0
9
0.00
-0.00
0.0
2.0
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: MSMED_GLATIRAMERACETATE – Use of glatiramer acetate
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).